advanced wound management News
-
Smith & Nephew joins world environment center to advance sustainable business practices
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, and the World Environment Center (WEC) jointly announced today that Smith & Nephew has been elected as WEC’s newest Corporate Member. Headquartered in London, England, Smith & Nephew operates in 32 countries, with major manufacturing operations in the U.S. and the U.K., as well as in Europe and ...
By 3BL Media
-
BioLargo Featured in SNN Live Interviews
BioLargo, Inc.'s president and CEO Dennis Calvert was recently interviewed by SNN Live at two investor conferences. Mr. Calvert introduces BioLargo and discusses the company's progress in commercializing its advanced iodine platform technology. Video of both interviews can be accessed by clicking on the following links. Marcum's 3rd Annual MicroCap Conference in New York City on May 29th. ...
-
BioLargo to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
BioLargo, Inc. (OTCQB: BLGO) will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9th at the New York Palace Hotel. Dennis Calvert, BioLargo's president, is scheduled to present at 2:55 p.m. ET. A webcast of the live presentation will be available at www.BioLargo.com where it will be retained for 90 days. A copy of the slides management will be ...
-
BioLargo`s product wins cat fancy magazine editor`s choice award
BioLargo, Inc. (OTCQB: BLGO) today announced that Cat Fancy Magazine awarded its Litter Deodorizing Concentrate an "Editor's Choice Award," naming it one of the 18 "Best Products of the Year" for 2013. Detailed in the December issue on newsstands now, the Cat Fancy editor commented, "I have four cats in a small house. After I started using this, I noticed an immediate reduction in odor and ...
-
BioLargo Secures Financing for Its Advanced Wound Care Products Targeting FDA Application, Approval and Commercialization Through Its Subsidiary Clyra Medical Technologies
BioLargo, Inc. (OTCQB: BLGO) subsidiary Clyra Medical Technologies, Inc. has successfully concluded a financing from Sanatio Capital LLC for $750,000 in equity and a forward commitment to provide a $5,000,000 operating line of credit, to support the FDA approval and commercial launch of Clyra's advanced wound care products. Clyra Medical Technologies holds the exclusive license to commercialize ...
-
BioLargo Assigned Federal and Military Supply System National Stock Number
Opens recurring sales channels for health care related products - Establishes working capital line of credit to support sales efforts - BioLargo, Inc. (OTCQB: BLGO) announced its subsidiary Odor-No-More, Inc. was assigned National Stock Numbers (NSNs) for multiple products by the Defense Logistics Information Service (DLIS), allowing the U.S. military, and federal and civil agencies, to ...
-
BioLargo Adds Wound Management Expert and Former VP at Smith & Nephew, Tanya Rhodes, to Its Team
BioLargo, Inc. (OTCBB: BLGO) announced today that former Smith & Nephew Vice President of Innovation (and Vice President at Smith & Nephew Wound Management) Tanya Rhodes has joined the BioLargo management team as a senior strategy advisor. Rhodes will work closely with BioLargo and its recently formed medical subsidiary to commercialize its technology in the wound management and medical ...
-
Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract
Imbed Biosciences Inc. (Imbed), a developer of next-generation therapies for tissue repair, and Spartan Medical, a veteran-owned Federal Contractor with fourteen years of flawless performance, jointly announced today that Imbed’s Microlyte® Matrix wound dressing portfolio has been added to Spartan Medical’s VA IDIQ Contract with the U.S. Department of Veteran Affairs (VA). The ...
-
Axio Biosolutions raises $6 million in a Series B2 equity round led by TrueScale Capital
Axio Biosolutions, a pioneering MedTech company, today announced a $6 million Series B2 equity raise led by TrueScale Capital, with participation from existing investors Omidyar Network India, University of California– Ratan Tata Fund, and Accel. Axio Biosolutions Private Limited, India (“Axio”), a wholly owned subsidiary of Boston-based Advamedica Inc. is a leading developer of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you